Harvard Bioscience (HBIO) investor relations material

Opening remarks and agenda

• The meeting was called to order by the CEO, who introduced the board members, independent auditor, and legal counsel present at the virtual-only meeting.

• Notice of the meeting was sent to all stockholders of record as of April 7, 2026, and a quorum was confirmed.

• Five business items were presented for consideration, including director elections, auditor ratification, executive compensation, and amendments to stock plans.

Board and executive committee updates

• Two Class II directors, Katherine Eade and John Duke, were nominated for three-year terms, with board recommendation for their election.

Shareholder proposals

• Proposals included election of directors, ratification of Grant Thornton as auditor, advisory vote on executive compensation, amendment to the employee stock purchase plan, and amendment to the 2021 incentive plan.

• The board recommended voting in favor of all proposals.